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Statement of Translational Relevance: RAS mutations that result in the unregulated activation of 
RAS signalling are common in cancer and a key unmet medical need. Therapeutic strategies that 
block RAS signalling could benefit many cancer patients suffering from KRAS mutant cancers.  
Preclinical studies indicate that combined MEK and AKT blockade can abrogate KRAS 
signalling. We conducted a combination Phase I study of a MEK inhibitor (selumetinib) and an 
AKT inhibitor (MK2206). 
To minimise the drug toxicities of this combination, while maximising antitumor activity, we 
evaluated several drug schedules. This trial demonstrates the complexity of drug combination 
trials and demonstrates that this combination strategy has antitumor activity against KRAS 
mutant cancers at tolerable doses. 
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ABSTRACT  
 
Purpose: KRAS is the most commonly mutated oncogene in human tumours. KRAS-mutant cells 
may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244; ARRY-
142886) and allosteric AKT inhibitors (such as MK-2206), the combination of which may 
overcome resistance to both monotherapies.  
Experimental Design: We conducted a dose/schedule-finding study evaluating MK-2206 and 
selumetinib in patients with advanced treatment-refractory solid tumours.  Recommended dosing 
schedules were defined as MK-2206 135 mg weekly and selumetinib 100 mg once-daily.  
Results: Grade 3 rash was the most common dose-limiting toxicity (DLT); other DLTs included 
grade 4 lipase increase, grade 3 stomatitis, diarrhoea, and fatigue, and grade 3 and grade 2 retinal 
pigment epithelium detachment. There were no meaningful pharmacokinetic drug-drug 
interactions. Clinical anti-tumour activity included RECIST 1.0-confirmed partial responses in 
non-small cell lung cancer and low-grade ovarian carcinoma.  
Conclusion: Responses in KRAS-mutant cancers were generally durable. Clinical co-targeting of 
MEK and AKT signalling may be an important therapeutic strategy in KRAS-driven human 
malignancies (Trial NCT number NCT01021748). 
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INTRODUCTION  
Kirsten rat sarcoma viral oncogene homolog (KRAS) is frequently mutated. This results 
in deregulated signalling via the Ras/Raf/mitogen extracellular signal-regulated kinase 
(MEK)/extracellular-signal-regulated kinase (ERK) pathway in human cancers, which promotes 
neoplastic transformation and maintenance of a malignant phenotype. Ras signalling may be 
activated through direct interactions with numerous growth factor receptors, or independently 
stimulated by somatically-acquired mutations in approximately 20% of human cancers, making 
this protein an important therapeutic target (1, 2). Nevertheless, to date, direct targeting of Ras 
activation by guanosine triphosphate (GTP) interaction has not been clinically feasible despite 
substantial research efforts (3). Furthermore, single-agent inhibition of downstream effector 
pathways through the use of MEK or protein kinase B (AKT) inhibitors has not led to significant 
clinical anti-tumour activity in KRAS-mutant tumours (4, 5). 
Numerous preclinical models have suggested that KRAS-mutant tumours require co-
targeting of the Ras/Raf/MEK/ERK and phosphotidylinositol 3-kinase (PI3K)/AKT pathways 
due to multiple points of cross-talk, negative feedback, and redundancy (6, 7). Inhibition of MEK 
by selumetinib in KRAS-mutant cancers can result in reactive up-regulation of AKT 
phosphorylation (8), whilst co-targeting of PI3K and MEK ablates this compensatory effect and 
results in superior anti-tumour efficacy, in contrast to inhibition of either pathway alone (9). 
Mutations in the PI3K/AKT and Ras/Raf pathways frequently co-exist in advanced cancers (10), 
while coactivating mutations are often found in treatment-resistant KRAS-mutant tumour models 
(11). For example, in KRAS-mutant cell lines treated with MEK inhibitors, activating PIK3CA 
mutations or PTEN loss lead to MEK inhibition resistance, which can be reversed by 
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coinhibition of the PI3K/AKT pathway (12). PIK3CA mutations concurrent with KRAS 
mutations appear to drive AKT signalling, restoring cyclin D1 expression and allowing G1-S cell 
cycle progression by underlying mechanisms independent of KRAS-mediated MEK/ERK 
signalling (13). Indeed, in a KRAS-mutant lung cancer mouse model insensitive to MEK 
inhibition alone, combined MEK and PI3K/mammalian target of rapamycin (mTOR) inhibition 
resulted in synergistic induction of tumour regression (14). Combinatorial inhibition of key 
nodes within signal transduction networks to overcome both de novo and acquired resistance has 
wide clinical applications (15), and preclinical data supporting the present combination are a 
successful example of this treatment strategy. 
We approached targeting KRAS-mutated tumours through the dual inhibition of two 
major downstream signalling pathways, RAF/MEK/ERK and PI3K/AKT. Two potent, allosteric, 
selective and orally administered inhibitors were combined: MK-2206, an allosteric inhibitor of 
AKT 1, 2, and 3 (IC50 = 8, 12, and 65 nmol/L, respectively), and selumetinib (AZD6244; ARRY-
142886), a non-ATP competitive inhibitor of MEK (IC50 = 10-14 nmol/L) (16, 17).  
 
METHODS  
Preclinical studies 
In vitro cell line models 
Determining the combination index by the Chou-Talalay method for cell lines treated with 
selumetinib and MK-2206 
Combinations of MK-2206 with AZD6244 were evaluated in 9 cancer cell lines with various 
mutational activations in the PI3K and/or MAPK pathways: 3 colon cancer cell lines (HCT116, 
HCT15, and HT29), 3 pancreatic cancer cell lines (AsPC-1, BxPC-3, and MIA-Pa-Ca2), 2 lung 
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cancer cell lines (Calu-6, NCI-H460), and 1 melanoma (A2058) cell line. Human cell lines were 
purchased from American Type Culture Collection (ATCC) which	  employs	  short	  tandem	  repeat	  (STR)	  profiling	  to	  ensure	  cell	  line	  authenticity.  The fixed-ratio experimental design 
originally described by Chou-Talalay was used (18). The in vitro anti-proliferative potencies 
(IC50) of selumetinib and MK-2206 as single agents were first determined separately to yield the 
IC50-selumetinib/IC50-MK-2206 ratio. A dilution series of selumetinib/MK-2206 combinations in which 
the ratio of selumetinib/MK-2206 was fixed and equal to the IC50-selumetinib/IC50-MK-2206 ratio was 
then prepared. Corresponding single-agent dilution series of selumetinib and MK-2206 were also 
prepared. The 3 dilution series were tested in the proliferation/viability assay (CellTiter-Glo 
Luminescent Cell Viability Assay; Promega). The data were analyzed using CalcuSyn software 
that calculates the combination index (CI) for each combination of selumetinib/MK-2206. CI 
<0.9 indicates synergism; CI = 0.9 to 1.1 indicates additivity; and CI >1.1 indicates antagonism. 
Enhanced apoptotic cell death was assessed by luminescence assay for caspase-3/7 activity after 
24 hours.  
 
In vivo studies 
CD1-nude mice bearing HCT116 tumour xenografts were selected as a model for study 
(Supplementary Table S1). Selumetinib at 25 mg/kg was orally administered twice daily (BID) 
on days 0–4 and days 7–11. MK-2206 at 120 mg/kg was orally administered once-­‐every-­‐other-­‐day (QOD) for 2 weeks.  
CD1-nude mice bearing A2058 tumour xenografts were selected as a model for study. 
Selumetinib at 25 mg/kg was orally administered BID on days 0–4 and days 7–11. MK-2206 at 
120 mg/kg was orally administered QOD for 2 weeks.  
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Clinical study 
This was a 2-part, Phase I study (Merck Sharp & Dohme Corp., MK-2206 Study Number 010; 
ClinicalTrials.gov identifier: NCT01021748) organized as below to achieve the following: 
• Dose finding: Identify the maximum-tolerated dose (MTD) of combination therapy with 
oral MK-2206 and oral  selumetinib (capsule formulation) in patients with locally 
advanced or metastatic solid tumours 
• MTD expansion: Confirm the MTD of combination therapy of oral MK-2206 and oral 
selumetinib (capsule formulation) in a select cohort of KRAS-mutant non-small cell lung 
cancer patients 
In the dose-finding portion of the study, sequential cohorts of 3–6 patients were enrolled 
into panels representing different dose levels of combination therapy to determine a preliminary 
MTD. The dose-escalation schedule initially followed a QOD schedule for MK-2206 in 
combination with selumetinib. Subsequent escalation included evaluation of the once-weekly 
(QW) dosing schedule of MK-2206 in combination with selumetinib. 
 Patients evaluated in the determination of dose-escalation decisions must have received 
≥80% of planned study combination therapy during the first 28-day cycle (unless they 
experienced a dose-limiting toxicity [DLT] prior to completing cycle 1). Patients who failed to 
begin trial treatment, or who did not complete at least 80% of study therapy, were replaced for 
determination of the dose-escalation decision. For any initial cohort of 3 patients, up to 3 
additional patients were enrolled (to make the total number of evaluable patients = 6) to further 
evaluate safety and tolerability. The dose level administered to each subsequent cohort of 
patients was to be determined based on the total number of DLT observed at the current dose 
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relative to the total number of patients treated and evaluable for DLT at the current dose. Dose 
escalation continued until the MTD or maximum planned dose was reached according to the 
modified toxicity probability interval (mTPI) approach (Supplementary Table S2). 
The study was conducted in accordance with Good Clinical Practice guidelines and in 
compliance with local and/or national regulations and in accordance with the ethical principles 
that have their origin in the Declaration of Helsinki. All patients gave informed consent, and 
approval was obtained from the ethics committees at each participating institution.	  
Patients were evaluated for tumour response using CT or MRI at baseline and every 8 
weeks during the study. Tumour response was assessed by RECIST (Response Evaluation 
Criteria in Solid Tumours) 1.0 (19). Where appropriate, different tumour markers were used to 
assess the effects of the combination treatment on the respective tumour types. Patients received 
MK-2206 and selumetinib until disease progression, intolerable adverse event, or consent 
withdrawal.  
 Sampling for pharmacokinetic determinations of MK-2206 and selumetinib (including 
the metabolite N-desmethyl selumetinib) was conducted during the first cycle of combination 
therapy. Pre-dose and serial post-dose specimens were taken on either days 1 and 22 (QW dosing 
schedules) or days 1 and 27 (QOD dosing schedules). Additional pre-dose collection time points 
included days 2, 3, 5, 8, 15, 23, 24, 26, and 29 for patients on the MK-2206 QW dosing schedule, 
and days 2, 3, 7, 15, 21, 28, and 29 for patients on the QOD dosing schedule. 
 Plasma (circulating nucleic acid) and archival tumour (formalin-fixed, paraffin-embedded 
tissue) specimens were collected at baseline. Analysis focused on PI3K or BRAF pathway 
activation events such as the mutation status of KRAS, BRAF, and PIK3CA. 
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RESULTS 
Previous preclinical studies of MK-2206 and selumetinib monotherapy each identified 
dose-dependent growth inhibition in tumour-bearing mouse models and showed evidence of 
target inhibition (20). We evaluated synergism between MK-2206 and selumetinib by conducting 
a fixed-ratio experiment as described by the Chou-Talalay method in 8 cancer cell lines derived 
from colon, pancreatic, melanoma, and lung cancers (18). Table 1 shows combination indices 
<0.9, the threshold for synergy, in all KRAS-mutant cell lines and cell lines driven by 
Raf/MEK/ERK and PI3K/AKT signalling. 
We then examined the effects of combined treatment on cell survival of KRAS-mutant 
HCT116 cells (containing the KRAS G13D mutation). Induction of activated caspase 3 and 7 in 
HCT116 cells was significantly higher after 24 hours of co-treatment with MK-2206 and 
selumetinib compared with either agent alone, as determined by luminescence assay (Fig. 1A). 
Fluorescence-activated cell sorting (FACS) cell-cycle profiles of HCT116 cells exposed to MK-
2206 and/or selumetinib for 72 hours showed that co-treatment resulted in the accumulation of a 
significantly greater proportion of cells in the sub-G1 phase than either MEK or AKT blockade 
alone (Fig. 1B). Inhibition of downstream signalling biomarkers was assessed by 
immunoblotting following incubation of cells with MK-2206 and/or selumetinib for 24 hours 
(Fig. 1C). Selumetinib alone blocked pT202/Y204 ERK completely, but incompletely 
suppressed pS235/236 S6 ribosomal protein (S6RP) and pT70 4E-BP1, and did not affect pS473 
AKT. In contrast, monotherapy with MK-2206 completely abrogated pS473 AKT, but 
incompletely inhibited pT70 4E-BP1, and had no effect on pT202/Y204 ERK or pS235/236 
S6RP. Combined treatment resulted in significant inhibition of pS473 AKT, pT202/Y204 ERK, 
pS235/236 S6RP, and pT70 4E-BP1. 
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Xenograft studies of KRAS-mutant HCT116 demonstrated inhibition of tumour growth by 
selumetinib, but little anti-tumour activity with MK-2206 alone (Fig. 1D; Supplementary Table 
S1). Combined treatment with MK-2206 and selumetinib resulted in moderate but significant 
increase in tumour regression over time compared with selumetinib alone. All treatments were 
well tolerated by the animals, with no mortalities or adverse clinical signs. A decrease in body 
weight was observed in tumour-bearing nude mice. The body weight reduction was very slightly 
enhanced by the combination (Supplementary Figure S1). 
In A2058 melanoma xenograft mouse models harbouring a BRAF V600E mutation and 
PTEN loss, but not KRAS or PIK3CA mutations, only modest anti-tumour activity was observed 
with MK-2206 and selumetinib monotherapy, while combination treatment again demonstrated 
enhanced anti-tumour responses (Supplementary Fig. S2; Supplementary Table S3). Preclinical 
in vivo toxicity studies for each agent alone indicated little evidence of overlapping 
histomorphological changes, with the exception of alterations in haemo-lymphatic and 
gastrointestinal tract systems at poorly tolerated doses in non-rodents. A decrease in body weight 
was observed in tumour-bearing nude mice with no mortalities or adverse clinical signs. The 
body weight reduction was very slightly enhanced by the combination (Supplementary Fig. S1).  
 
Clinical Studies 
Based upon the strong scientific rationale for the co-inhibition of AKT and Ras/Raf 
pathways, and preclinical evidence of synergy and tolerability, we initiated a phase I clinical 
study combining MK-2206 and selumetinib. No formal drug-drug interaction studies were 
conducted to assess the potential for an interaction between selumetinib and MK-2206, as the 
risk of a drug-drug interaction was considered low based upon the metabolism of each drug.  
12 
 
Specifically, neither of these drugs is a potent inhibitor of CYP1A2, CYP2C19, or CYP3A4 and 
although both selumetinib and MK-2206 are substrates of P-glycoprotein, selumetinib is not an 
inhibitor and MK-2206 is only a weak inhibitor of this transporter.  We had previously 
characterized the pharmacokinetic (PK) and pharmacodynamic profile of each drug in studies 
with paired tumour biopsies (16, 17, 21). The maximum-tolerated dose (MTD) for MK-2206 is 
60 mg QOD, or 200 mg weekly. At 60 mg QOD, the terminal half-life (t1/2) of MK-2206 was 
71.3 hours and the median suppression of post-dose tumour pS473 AKT was 81%. For 
selumetinib, the hydrogen sulphate oral capsule formulation was used, with prior phase I trials 
having established the MTD as 75 mg BID and the terminal t1/2 as 5.3 hours (16) with this 
formulation; previously a dose of 100 mg BID with freebase powder formulation had been 
established (21). Suppression of pERK at 6 hours was observed in both peripheral blood 
mononuclear cells and paired tumour biopsies. Clinical toxicities of MK-2206 were mainly 
erythematous maculopapular rash and stomatitis, whereas those for selumetinib included 
acneiform dermatitis, diarrhoea, fatigue, nausea, and peripheral oedema. Rash was a dose-
limiting toxicity (DLT) for both drugs, likely reflecting on-target effects of AKT and MEK 
inhibition for MK-2206 and selumetinib, respectively. 
In this phase I study, initial cohorts of 3–6 evaluable patients with advanced, treatment-
refractory solid tumours were recruited and given combinations of MK-2206 and selumetinib. 
Additional patients were enrolled to evaluate tolerability according to the mTPI approach as 
reflected in Supplementary Table S2. Fifty-one patients received treatment during the dose-
escalation portion of the study, with 46 evaluable for dose-escalation safety assessment (Table 
2). Five patients were considered non-evaluable for the dose escalation safety assessment 
because they did not complete ≥80% of the first cycle of treatment or due to either non-
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compliance with study medication (n=2), or non–dose-limiting toxicity (n=3; 1 of the 3 patients 
experienced rapid disease progression and was discontinued after 1 week of therapy). Dose 
escalation of either or both drugs aimed to define the MTD as the highest dose at which <20% 
patients experienced a DLT (22). A dose-expansion cohort at the MTD recruited an additional 11 
patients with KRAS-mutant non–small-cell lung cancer (NSCLC); this cohort was selected based 
on preclinical anti-tumour activity (20)—observed anti-tumour activity during dose escalation 
(Fig. 2)—and was further supported by data from a parallel randomised phase II trial showing 
activity of selumetinib in combination with docetaxel in advanced KRAS-mutant NSCLC (23). 
The starting dose for combination therapy was MK-2206 45 mg QOD, which represented 
75% of the QOD MTD (60 mg), administered with the monotherapy MTD of selumetinib 75 mg 
BID of selumetinib.. However, combined treatment at this dose resulted in an unacceptably high 
rate of DLT, with 2 of 3 evaluable patients having National Cancer Institute Common Toxicity 
Criteria (NCI-CTCAE) version 3.0 grade 3 maculopapular rash (Supplementary Fig. S3). At 45 
mg QOD of MK-2206 and selumetinib 75 mg once daily (QD), grade 1 rash and grade 3 
diarrhoea were reported, but no DLT were observed. This dose was determined to be the MTD of 
QOD dosing of MK-2206 with selumetinib.  
The MK-2206 schedule was then changed to QW dosing based on monotherapy studies 
demonstrating its long terminal elimination half-life, reduced drug accumulation, improved 
tolerability, and pharmacodynamic data suggesting ongoing target inhibition at day 5 post-dose 
(17). The initial combination schedule of MK-2206 90 mg QW with selumetinib at 75 mg BID 
was not tolerable, with DLT of grade 2 retinal pigment epithelium detachment and grade 3 
stomatitis and dermatitis acneiform observed in 3 out of 7 evaluable patients. Subsequent dose 
levels required dose and schedule modifications from this starting dosing schedule. Doses of 
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MK-2206 at 135 mg QW with selumetinib 100 mg QD resulted in only 1 of 6 DLT, comprising 
grade 3 fatigue, and this was therefore defined as the recommended phase II dose. Further 
exploration of this dose level in an additional 11 patients (all evaluable) confirmed this dose to 
be well tolerated, with only 2 further patients experiencing DLT of grade 3 rash and stomatitis 
(Table 3). 
The most common drug-related adverse events (occurring in >5 patients) are summarized 
in Supplementary Table S4. Rash was the most frequent adverse event and DLT;  two distinct 
appearances were noted: a reversible maculopapular rash associated with pruritus consistent with 
our previous experience with MK-2206 (17); and an erythematous acneiform rash associated 
with selumetinib that improved with topical steroids or oral tetracycline therapy (24). Other DLT 
included diarrhoea and stomatitis, which appeared to be dose-related. No drug-related 
haematological toxicities were observed in this study. Infrequent asymptomatic grade 3 increases 
in circulating hepatic transaminases also were reported (n=5), but fully normalised on temporary 
discontinuation of the drug. Dose-limiting detachment of retinal pigment epithelium (RPED), 
which was observed in 2 patients, was reversible following discontinuation of treatment.  
Pharmacokinetics suggested no meaningful drug-drug interaction between MK-2206, 
selumetinib, and the active metabolite N-desmethyl selumetinib. At the combination MTD, the 
terminal t1/2 of MK-2206 was 61.7 ± 15.2 hours, within range of that seen in monotherapy (88.9 
± 26.9). Published monotherapy PK data for selumetinib 100 mg capsule is not available for 
direct comparison with the combination MTD. However, exposure (mean Cmax and tmax) 
following 75 mg selumetinib plus MK-2206 was within the range previously reported for 
monotherapy at the same dose (16). Exposure to selumetinib increases proportionally with dose 
(16), and therefore was slightly higher in the combination MTD cohort treated with selumetinib 
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100 mg QD (mean Cmax 1140 ng/mL [range 554-2540] and AUC0-10h 4500 ng.h/mL [range 2297-
7875]) than cohorts given 75 mg selumetinib. 
Inter-patient variability was moderate for MK-2206 (%CV of Cmax and AUC0-168h ranged 
from 33% to 47%), and high for selumetinib (%CV of Cmax and AUC0-10h ranged from 19% to 
74%). Preclinical models associated anti-tumour activity with MK-2206 concentrations above 57 
nmol/L, a concentration at which >70% inhibition of pS473 AKT was achieved; this target 
steady-state trough concentration of >57 nmol/L was achieved in 100% of patients in 48 hours at 
the 135 mg QW MTD level. In previous monotherapy studies, we have shown that pAKT and 
pERK were robustly suppressed at the exposures achieved at the combination MTD of MK-2206 
(135 mg QW) and selumetinib (100 mg QD), respectively (16, 17, 25).  
In this study, 29 patients with KRAS-mutant cancers were treated, for whom confirmed 
RECIST (Response Evaluation Criteria in Solid Tumours) 1.0 partial responses were observed in 
3 of 13 (23%) patients with NSCLC, and 1 of 2 (50%) patients with ovarian cancer. The best 
anti-tumour responses were observed in a 59-year-old Caucasian female with chemotherapy-
refractory KRAS-mutant lung adenocarcinoma. Overall, she had a 71% RECIST response and 
remained on treatment for 15 months. A 63-year-old patient of Asian ethnicity with 
chemotherapy-refractory KRAS-mutant lung adenocarcinoma also had a 45% RECIST response 
and remained on study for 20 weeks (Fig. 3). One additional patient with pancreatic cancer 
achieved a RECIST partial response, and although KRAS mutations are known to occur in 
approximately 85% in pancreatic ductal carcinoma (26), mutation status was not available for 
this patient. RECIST stable disease >6 months was observed in 1 patient with NSCLC and 
another with low-grade ovarian cancer. In contrast, none of the 33 patients with confirmed KRAS 
wild-type tumours achieved a confirmed RECIST partial response or stable disease >6 months. 
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Interestingly, no confirmed objective responses were observed in the colorectal cancers with 
KRAS mutations (n=11; Fig. 2). 
The majority of KRAS mutations were amino acid substitutions to cysteine (21%), valine 
(34%), or aspartate (14%) in codon 12. The type of KRAS mutation, or presence of concurrent 
PIK3CA or BRAF mutations, did not appear to influence whether an objective response was 
achieved, though notably, the limited number of responders in this study prevented us from 
drawing a definitive conclusion. Among patients with NSCLC, 2 of 13 patients (15.4%) had 
concurrent PIK3CA mutations detected, while 0 of 9 patients with colorectal cancer (CRC) had 
concurrent PIK3CA mutations detected. 
DISCUSSION 
While single-agent activity for MEK inhibitors in clinical KRAS-mutant disease has been 
modest, Raf/MEK/ERK signalling is considered to be a major Ras effector pathway (4, 5). The 
activity we observed in KRAS-mutant models appeared largely driven by selumetinib, which is 
consistent with findings from other preclinical models combining MEK and mTOR inhibitors in 
this setting (8). Therefore, based on these data, we attempted to prioritize maintenance of MEK 
blockade, while also attempting to combine AKT inhibition. This trial highlights the multiple 
challenges of combining targeted agents (27). The numerous permutations of dose, schedule, and 
sequence result in significant complexities, and there are currently no standardized trial designs 
to assess optimal combination strategies. The particular challenge of combining MEK and AKT 
inhibition included known overlapping monotherapy toxicities, especially rash and diarrhoea that 
were observed at the MTD of both selumetinib and MK-2206 (17, 21). Rash and diarrhoea 
expectedly limited dosing and ultimately required de-escalation of both MK-2206 and 
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selumetinib to improve tolerability of the combination. Although de-escalation of both 
selumetinib and MK-2206 from recommended monotherapy doses was required to mitigate 
tolerability issues, both drug doses at the combination MTD were previously shown to be 
biologically active in their respective single-agent studies. In this study, we successfully changed 
schedules of administration of both drugs (compared with single-agent phase I schedules and 
doses) to improve tolerability and is an example of how flexible design of early clinical trials can 
help circumvent toxicity (27). The pharmacokinetic data in this study suggested no drug-drug 
interaction between selumetinib and MK-2206, which supported the pre-clinical assessment of 
the combination having a low potential for interaction.  However, as no formal drug-drug 
interaction assessment studies were conducted, this result must be interpreted with caution. 
Clinical anti-tumour activity was observed with durable RECIST tumour shrinkage in KRAS-
mutant NSCLC and low-grade ovarian carcinoma. However, no responses were observed in 
KRAS-mutant colorectal or small-bowel carcinoma, possibly suggesting distinct biological 
context differences in these diseases. As this trial did not include prospective screening of 
concurrent mutations for study entry, the number of subjects where both KRAS and PIK3CA 
mutations were detected was very limited and precluded our ability to draw firm conclusions 
around whether these concurrent mutations could be associated with response in the 
clinic.  Colorectal cancer has previously shown limited success to treatment with MEK inhibitor 
monotherapy (28). The observed heterogeneity of response among patients with KRAS-mutant 
cancers likely reflects the complexities of tumour biology and possibly the presence of other 
aberrant driver mutations or disruption of signalling feedback loops (29), although we have not 
excluded poor drug penetration to tumour in these studies. Furthermore, there may be 
mechanisms independent of PI3K and MEK that lead to maintenance of cellular proliferation, 
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such as up-regulation of p21-activated kinase (30) or LKB1 mutations (31). Ultimately, the 
selection of molecularly targeted agents to combine on the basis of molecular profiling remains a 
challenging and imperfect strategy, requiring the ever-evolving application of an array of modern 
technologies, including DNA sequencing, genomics, bioinformatics, and computational 
approaches (15). 
A combination of selumetinib and docetaxel was recently evaluated in a phase II study 
with KRAS-mutant NSCLC patients, demonstrating an improvement in response rate, 
progression free survival (5.3 months vs 2.1 months) and median overall survival (OS) in the 
selumetinib combination arm compared with docetaxel alone (9.4 vs. 5.3 months), although the 
combination resulted in more toxicities (23).  
In conclusion, these are the first clinical data to demonstrate that different KRAS-mutant 
cancers may show differential sensitivity to the co-targeting of MEK and AKT and to present a 
novel and rational anti-tumour strategy against cancers driven by a common driver mutation. 
Multiple other drug combinations targeting different components of the Ras/Raf and PI3K/AKT 
signalling pathways have also entered clinical development based on robust preclinical biology. 
We envision that the complex and multifaceted clinical evaluation of these drug combinations 
will lead to a new therapeutic avenue for many RAS-mutant cancers, including KRAS-mutation 
driven NSCLC and low-grade ovarian cancer. Moreover, as with other rationally designed 
molecularly targeted strategies (e.g., poly[ADP-ribose] polymerase [PARP] inhibitors in 
BRCA1/2-mutant cancers), we have observed anti-tumour activity in patients whose tumours 
have the same molecular defect, but which arise from diverse geographical origins (lung, ovary, 
and pancreas) (32). Due consideration must continue to be given in oncological drug 
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development and registration studies to select patients based, not simply on disease origin, but 
also on the underlying cancer biology. 
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Table 1. Combination index (CI)†  by Chou-Talalay method for selumetinib and MK-2206‡   
Cell line Cancer 
type 
KRAS PIK3CA BRAF PTEN CI: 
ED50 
CI: 
ED75 
CI: 
ED90 
HCT116 Colon G13D H1047R WT WT 0.20 0.14 0.11 
HCT15 Colon G13D E545K WT WT 0.12 0.12 0.12 
HT29 Colon WT P449T V600E WT 0.68 0.73 0.82 
A2058 Melanoma WT WT V600E Del 0.35 0.19 0.12 
AsPC-1 Pancreatic G12D WT WT  WT 0.18 0.09 0.15 
MIA-Pa-
Ca2 
Pancreatic G12C WT WT WT 0.42 0.25 0.58 
Calu-6 Lung Q61K WT WT WT 0.25 0.20 0.18 
HCI-H460 Lung Q61H E545K WT WT 0.04 0.03 0.02 
†Cell Lines were studied across two-fold serial dilutions spanning the IC50 for each cell line for each individual 
drug.  Shown is the combination index (CI) which calculates the combination effects as a function of the slopes of 
the inhibition curves independent of any specific drug concentration 
‡An additional analysis was performed on an expanded set of colorectal cancer cell lines harboring either wildtype 
or mutant K-RAS, B-RAF or PIK3CA were analyzed for sensitivity to MEKi or AKTi + MEKi.  The results suggest 
that PIK3CA mutant status predicts resistance to single agent MEKi treatment while combination treatment of AKTi 
+ MEKi reversed this effect.  MEKi sensitivity was not altered in the presence of either wildtype or mutant K-RAS 
or B-RAF status in these lines. 
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Table 2. Patient demographics  
Patient characteristics No. of patients (%) 
Number of patients  62 
Age, years 
Median 58 
Range 33–81 
Performance status  
0 22 (35) 
1 40 (65) 
Male/females 26/36 (42/58) 
Patients with prior chemotherapy 62 
Median number of prior chemotherapy regimens 3 
Range 1–10 
Tumour types Total 
Non–small-cell lung  19 (31) 
KRAS mutant 13 (21) 
Colorectal 14 (23) 
KRAS mutant 9 (15) 
Ovarian 5 (8) 
KRAS mutant 2 (3) 
Pancreatic 5 (8) 
KRAS mutant 4 (6) 
Breast 3 (5) 
Leiomyosarcoma 3 (5) 
Ewing’s sarcoma 2 (3) 
Prostate 2 (3) 
Melanoma 2 (3) 
Appendix, cervical (squamous), chondrosarcoma, 
esophageal, liver, Merkel cell, thyroid  
7 total [1 each] 
(11 [2]) 
KRAS mutant 1 (2) 
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Table 3. Related grade 3/4 adverse events (AEs) 
     Patients with C1-
related grade (Gr) 3/4 
AEs  
Patients with 
C≥2-related Gr 
3/4 AEs 
Dose 
level 
 
MK-
2206 
Selumetinib n  
(evaluable 
for safety) 
DLT 
n (%) 
Event n Event n 
QOD-
1 
45 mg 
QOD 
75 mg BID 4 (3) 2 
(66.7) 
Gr 3 rash 
 
2a Gr 3 ALT/AST 
elevation 
1 
QOD-
1 
45 mg 
QOD 
75 mg QD 6 (6) 0 (0) Gr 3 diarrhoea 
 
1 None 0 
QW-1 90 mg 
QW 
75 mg BID 9 (7) 3 
(42.8)b 
Gr 3 stomatitis 
Gr 3 rash 
1a 
1a 
Gr 3 anaemia 
Gr 3 fatigue 
Gr 3 retinal 
pigment 
epithelium 
detachmentb 
1 
1 
1 
QW-
1a 
90 mg 
QW 
75 mg QD 7 (6) 1 
(16.7) 
Gr 3 diarrhoea 1a Gr 3 ALT 
elevation 
 
1 
QW-
1b 
90 mg 
QW 
50 mg BID 7 (6) 2 
(33.3) 
Gr 3 rash 2a Gr 3 CPK 
elevation 
Gr 3 diarrhoea 
1 
 
1 
QW-
1c 
90 mg 
QW 
100 mg QD 3 (3) 0 (0) None 0 None 0 
QW-
1d 
90 mg 
QW 
150 mg QD 3 (3) 2 
(66.7) 
Gr 4 lipase 
elevation 
Gr 3 retinal 
pigment 
epithelium 
detachment 
1a 
 
1a 
None 0 
QW-
1ec 
135 mg 
QW 
100 mg QD 17 (17) 3 
(17.6) 
Gr 3 fatigue 
G3 lymphocyte 
count 
decreased 
Gr 3 pruritus 
Gr 3 rash  
 
Gr 3 stomatitis 
1a 
1 
 
 
1 
3a (1 
DLT) 
1a 
Gr 3 ALT/AST 
elevation 
Gr 3 dry skin 
Gr 3 pruritus  
Gr 3 rash  
 
1 
 
1 
1 
3 
 
QW-
1f 
100 mg 
QW 
100 mg QD 6 (6) 0 (0%) None  None 0 
DLT = dose-limiting toxicity. 
No grade 5 events considered by the investigator to be related to either drug were reported. 
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aEvent counted as DLT. 
bOne grade 2 DLT of retinal pigment epithelium detachment was observed during cycle 1 in the 
same patient who experienced a grade 3 event after beginning cycle 2. 
cDose	  considered	  the	  maximum-­‐tolerated	  dose	  (MTD)	  for	  the	  combination;	  6	  enrolled	  in	  dose	  escalation	  period,	  11	  KRAS	  mutant	  NSCLC	  enrolled	  in	  confirmation	  period.	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Figure Legends 
Fig. 1. Activated caspase induction, cell-cycle profiles, and pERK/pAKT profiles of HCT116 
cell lines and HCT116 xenografts in rodents treated with MK-2206 and/or selumetinib. (A) 
Caspase-3/7 activity after 24 hours was determined by luminescence assay. Data was indicated 
as fold induction of caspase against the signals of DMSO treated cells. (B) Percent of sub-G1 
population in cell cycle was determined with FACS when HCT116 cells were exposed with MK-
2206 and/or selumetinib for 72 hours. (C) HCT116 colon cancer cells were treated with MK-
2206 and/or selumetinib at the indicated concentration for 24 h. The cell lysates were analyzed 
by Western blot with the indicated antibodies. (D) Selumetinib alone showed potent anti-tumor 
efficacy in this animal model. However, MK-2206 had only marginal anti-tumour effect. The 
combination therapy produced a tumour regression with statistically significant increase in the 
anti-tumour response as compared to monotherapy (P<0.05). 
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Fig. 2. Waterfall plot of RECIST responses in evaluable patients with KRAS-mutant cancers. 
aThese data only reflect subjects who were re-evaluated after the baseline scan; bRecommended 
phase II dose for the combination. 
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Fig. 3. Example responder: KRAS-mutant adenocarcinoma of lung. A 63-year-old female never-
smoker of Asian ethnicity with metastatic adenocarcinoma of the lung, which was KRAS G12D 
mutant, but wildtype for epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase 
(ALK), PIK3CA, and BRAF gene aberrations. Figures 3 A and B represent pretreatment scans, 
while the Figures 3 C and D represent the same slices of scans with best response to the 
treatment. This patient’s prior treatments included (I) cisplatin and pemetrexed (2 cycles with 
disease progression); (II) carboplatin and paclitaxel (8 cycles with partial response); (III) 
docetaxel (2 cycles with disease progression); (IV) carboplatin and paclitaxel rechallenge (2 
cycles with disease progression); (V) radiotherapy to spine metastases. She was treated with 
MK-2206 135 mg PO QW and selumetinib100 mg PO OD without dose reduction, although she 
had a grade 2 skin rash that was tolerable. She had a RECIST partial response with 45% 
reduction in the sum of diameters of the target lesions. The patient eventually developed 
progressive disease after 6 cycles due to the development of symptomatic brain metastases. 
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Supplementary Table S1. CD1-nude mice bearing HCT116 tumour xenografts. *At day 10, % 
tumour volume compared with control. 
 
 
 
 
  
Supplementary Table S2. Dose-decision guidelines. E = Escalate to the next higher dose; S = 
Stay at the current dose; D = De-escalate to the next lower dose; U = Current dose is 
unacceptably toxic. Toxicity was graded according to the National Cancer Institute Common 
Toxicity Criteria, version 3. 
 
 
  
Supplementary Table S3. CD1-nude mice bearing A2058 tumour xenografts. *At day 10, % 
tumour volume compared with control. 
 
 
  
 
Supplementary Table S4. Adverse events (worst grade, >5 patients overall) related to MK 2206 
and selumetinib as a function of dose during the first course (and all courses). Values represent 
the number of drug-related adverse events in the first course (and in all courses) of treatment. 
Only the highest grade is counted for an individual subject. There were no grade 5 adverse 
events considered by the investigator to be related to either drug. 
 
Figure Legends. 
Supplementary Fig. S1. Effect of MK-2206 in combination with selumetinib on body weight. A 
decrease in body weight was observed in tumour-bearing nude mice. The body weight reduction 
was very slightly enhanced by the combination. 
 
Supplementary Fig. S2. Treatment with MK-2206 or selumetinib alone had moderate anti-
tumour effects. The combination therapy produced a statistically significant increase in the anti-
tumour response as compared to monotherapy (P<0.05). 
 
Supplementary Fig. S3. A 61-year-old male patient with metastatic adenocarcinoma of the 
jejunum at cycle (C) 1, day 21 with a grade III maculo-papular rash with pustules and 
desquamation. This patient received a dose of MK2206 90mg PO QW and selumetinib 50mg 
BD. He initially presented on C1D8 with a grade I maculo-papular rash; this became a grade II 
rash on C2D15, which was treated with a course of oral antibiotics and topical steroid cream. 
Continued drug treatment led to a grade III rash on C1D21 (pictured) when drug was stopped for 
a 1-week break along with an extended course of antibiotics. The rash resolved to grade I on day 
28 after 1 week’s break. 
  
Supplementary Fig. S1.  
 
  
Supplementary Fig. S2. 
 
 
 
 
 
 
  
 
 
 
Supplementary Fig. S3.  
 
 	  
